Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.
Mult Scler Relat Disord
; 49: 102777, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1036334
ABSTRACT
We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Monoclonal, Humanized
/
COVID-19
/
Antibodies, Viral
/
Multiple Sclerosis
Type of study:
Case report
/
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2021
Document Type:
Article
Affiliation country:
J.msard.2021.102777
Similar
MEDLINE
...
LILACS
LIS